Anzeige
Mehr »
Mittwoch, 27.08.2025 - Börsentäglich über 12.000 News
Patentschutz bis in die 2040er - Biotech-Geheimtipp vor möglichem Fast-Track-Durchbruch in den USA!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C46P | ISIN: US19243B1026 | Ticker-Symbol:
NASDAQ
26.08.25 | 22:00
2,855 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COGNITION THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
COGNITION THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur COGNITION THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCognition Therapeutics regains Nasdaq compliance on $1.00 bid price rule1
DiCognition Therapeutics regains Nasdaq compliance with $1 share price2
DiCognition Therapeutics, Inc.: Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement68PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative...
► Artikel lesen
DiCOGNITION THERAPEUTICS INC - 8-K, Current Report2
13.08.Cognition Therapeutics stock jumps after FDA confirms Phase 3 design7
COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln
13.08.Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug2
12.08.Cognition Therapeutics aligns with FDA on Alzheimer's drug phase 3 design16
12.08.Cognition Therapeutics, Inc.: Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease185- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:...
► Artikel lesen
07.08.Cognition Therapeutics GAAP EPS of -$0.11 misses by $0.012
07.08.COGNITION THERAPEUTICS INC - 8-K, Current Report2
07.08.COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report2
29.07.Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease1
21.07.Cognition Therapeutics reports positive results for Alzheimer's drug4
21.07.Cognition Therapeutics: Positive Studiendaten für Alzheimer-Wirkstoff Zervimesin1
21.07.Cognition Therapeutics, Inc.: Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease1
16.07.Cognition Therapeutics stock soars after DLB study results4
16.07.Cognition Therapeutics: Aktie legt nach vielversprechenden Studiendaten zu Demenzmittel zu19
16.07.Cognition Therapeutics, Inc.: Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC138- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo...
► Artikel lesen
12.07.Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress2
10.07.Cognition Therapeutics stock soars after FDA meeting on Alzheimer's drug4
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1